• KKE Oil is expected to be the first in a full suite of recreational products to be launched through a partnership between Supreme Cannabis Company and Khalifa Kush Enterprises Canada
• The KKE Oil line is anticipated to be available early July 2019 in Alberta, Canada, and by the end of this week in British Columbia and Ontario
• Canada will be the first country outside of the United States to have KKE products available for purchase

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), in partnership with Khalifa Kush Enterprises Canada, is debuting a new line of cannabis oils named KKE Oils. The offering is the first in a suite of new products from the partnership, the companies jointly announced (http://ibn.fm/34Xuj).

KKE Oil is a recreational-focused oil that offers the consumer high THC potency and precise dosing in a cannabis oil. The line is one of the first recreational-focused cannabis oils in Canada. Wiz Khalifa and the KKE team specifically chose Supreme Cannabis subsidiary 7ACRES’ Sensi Star strain for the launch.

Supreme Cannabis president and founder John Fowler described his excitement about the joint venture, praising the high quality of KKE Oil. “KKE Oils are easy to consume, effective and deliver the aromatic terpene profile 7ACRES’ Sensi Star is known for,” Fowler said in a news release. “We can’t wait to launch the full suite of KKE products, including KKE Jean Guy Oil, later this year.”

Canada will be the first country outside the United States to have KKE products available for purchase, with a national rollout planned throughout the year. KKE Oil is available in British Columbia and Ontario, with Alberta following this week. Other Canadian provinces will receive the products in the coming months, the companies announced.

“I’m excited to bring our first products to Canada and launch KKE Oils,” KKE principal Wiz Khalifa added. “They are an awesome high-in-THC product that everyone will love. This is a legendary moment that will be followed by many more game-changing releases KKE will launch with Supreme Cannabis over the next year.”

Supreme Cannabis is a Toronto-based company focusing on its strategy of pursuing opportunities and generating sustainable growth in what it sees as an emerging global market. Khalifa Kush Enterprises Canada was founded in 2018 and is the first expansion for Khalifa Kush outside the United States.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• The fast-growing hemp market is driving intense competition, with innovative cultivation practices serving as a major factor of differentiation
• Hemptown’s cultivation methodology, paired with a genetic modification advantage, is expected to lead to increased yields and lower costs
• The company is scaling up operations to meet rising demand; it anticipates up to $200 million in revenue by 2020

Legislative changes in the U.S. and other parts of the world, as well as changing consumer attitudes, are contributing to the rapid expansion of the hemp products market. The industrial hemp market is anticipated to grow at a CAGR of 18.3 percent through 2027 (http://ibn.fm/Hstkn). Market research indicates that the CBD segment is the one that will grow the most, with some forecasts suggesting that that the CBD product market could reach $20 billion by 2024 (http://ibn.fm/4xDh6). Combined with THC products, this market is on course to reach more than $45 billion by 2024.

Such lucrative forecasts are contributing to the establishment of numerous producers and CBD companies. To be successful, however, these enterprises need some competitive advantage.

One of the biggest strengths in the future will come from an ability to maximize hemp yields and bring down production costs. Companies like Hemptown USA are changing hemp cultivation through technology to keep production costs low and optimize yields.

Hemp Production Cost: A Numbers Game

Yields from hemp are highly variable and dependent on numerous factors. Soil type, irrigation effectiveness, control of pests and seed genetics all play a role in determining the effectiveness of agricultural processes.

Since many companies currently compete to establish leading positions within the lucrative market, maintaining optimal prices is one of the key essentials. The goal cannot be accomplished whenever yields are insufficient or the agricultural process is too expensive. Apart from cultivation and agricultural factors, economic principles also have to be taken into account for the determination of hemp price trends in the future.

Reports suggest that the price of hemp went up after the passing of the federal Farm Bill (http://ibn.fm/CG8NG). Some forecasters suggest that it will remain elevated due to the high demand and growers’ current inability to meet it.

Main Factors Impacting Hemp Production Prices

Hemp doesn’t grow well on wet soils or in those featuring a heavy clay content. Right from the start, the number of plots available for effective cultivation is limited.

Additionally, hemp is a short-day plant. It starts to mature only when the day length falls under 12 hours of sunlight. This means that growers have a limited amount of time to produce the crop, if they plan to do outdoor cultivation.

Currently, there are no herbicides in the U.S. labeled for use on hemp (http://ibn.fm/K0EHN). This means that weed control has to happen mechanically – the old-fashioned way, by hand. Furthermore, hemp can be affected by diseases, pests and insects. All of these factors need to be controlled for the yield to be optimal and the cost of production to remain reasonable.

Growers also need to focus on characteristics of the hemp seed, one of the most important parts of the plant (http://ibn.fm/fNqf2). They have to work on increasing the size, the CBD content and improving the seed’s shattering resistance. Such goals can be accomplished through technology and genetic modifications.

Modern Technology to the Rescue

Innovative hemp cultivation practices allow for the optimization of plant yield and the reduction of costs. Companies like Hemptown have established themselves as low cost producers, because they control all of the variables that may reduce effectiveness.

One of the easiest ways to increase yields and eliminate waste involves controlling environmental factors (http://ibn.fm/Eetxk). State-of-the-art hemp facilities can accomplish the goal in several distinctive ways.

Hemptown employs a “soil to oil” methodology that involves experienced professionals working in a few selected agricultural microclimates across Oregon’s Emerald Triangle, Kentucky and Colorado. In 2018, Hemptown harvested 110,000 pounds of full-spectrum biomass with CBD content of approximately 17 percent from the Oregon hemp farm.

In 2019, the company is scaling up operations to meet the growing market demand for affordable hemp and CBD oil. As per initial estimates, it will cultivate over one million pounds of hemp. By 2020, the company’s projected revenue will reach $100 million to $200 million as the additional farming operations reach full capacity.

Genetic modifications and control over the seeds provide additional opportunities for reducing the cost of hemp production. In addition, such innovative practices allow for the cultivation of hemp plants that have highly desirable characteristics.

Hemptown has the rights to one million rare cannabigerol (CBG) seeds that are genetically modified to yield anywhere between 15 and 20 percent full-spectrum cannabinoids. This fact positions Hemptown as one of the future leaders in the CBG oil production market, a fast-growing segment of the cannabinoid market due to the multiple uses and benefits associated with CBG.

For more information, visit the company’s website at www.HemptownUSA.com

• Research indicates that anti-inflammatory medications have the power to prevent the onset and control the symptoms of Alzheimer’s disease
• The link between inflammatory processes and Alzheimer’s has long been established; companies like INmune Bio are working to further the research and develop safe and effective drugs based on disrupting this mechanism
• INmune Bio has received a $1 million grant from the Alzheimer’s Association to bring its lead drug candidate, XPro1595, to the clinical testing stage

Could tumor necrosis factor-alpha (TNF-α) inhibition be the next big thing in the world of Alzheimer’s disease (AD) treatment? A detailed Washington Post report focuses on research carried out by a Pfizer Inc. (NYSE: PFE) team (http://ibn.fm/CcAUJ). According to the researchers, one of the company’s rheumatoid arthritis anti-inflammatory drugs appeared to reduce the risk of Alzheimer’s disease development by as much as 64 percent.

Pfizer researchers went through thousands of insurance claims in 2015, reaching the conclusion that the rheumatoid arthritis pharmaceutical had such an effect on AD. Carrying out a clinical trial to prove the findings, however, would have been an expensive endeavor in this case, with uncertain results, causing Pfizer to hold off.

A presentation prepared for review by an internal Pfizer committee in February 2018 noted that the drug (Enbrel) could “potentially safely prevent, treat, and slow progression of Alzheimer’s disease.” This suggests that the right approach to TNF-α inhibition medication has promise. TNF is an inflammatory cytokine that plays an important role in both inflammation and the body’s immune response. Soluble TNF (sTNF) is found circulating in the blood stream, and it has been linked to inflammatory processes, infections and even cancer.

Some members of the scientific community have pushed for further testing of the mechanism. According to these professionals, further examination of anti-inflammatory medications in the treatment of AD is warranted, because such investigations could highlight new mechanisms for the effective control and treatment of the condition.

Several pre-clinical studies have shown a connection between inflammation and Alzheimer’s disease pathology. In one of these trials, XPro1595 by INmune Bio Inc. (NASDAQ: INMB) prevented the accumulation of C-terminal amyloid beta protein. The conclusion reached was that the inhibition of soluble TNF signaling prevents pre-plaque amyloid-associated neuropathology, a risk factor implicated for its link to AD.

A link between TNF and AD has also been established in the clinic. Alzheimer’s disease patients have elevated serum levels of TNF. In addition, high TNF levels are seen to cause people who have mild cognitive impairment to progress to AD.

XPro1595 is an engineered protein that’s almost the same as sTNF. There are only two-point mutations in the coding sequence, and XPro1595 is formulated to keep sTNF from binding to TNFR – a mechanism that has been studied and shown to reduce pro-inflammatory signals.

A lot more work needs to be done on XPro1595, and, to advance the pursuit of medication for AD treatment, INmune Bio has secured a $1 million grant from the Alzheimer’s Association. With the funding, INmune Bio hopes to speed up pre-clinical research and help pharmaceutical developers move on to clinical testing.

Through the grant, INmune will carry out a phase 1 clinical trial in 18 patients suffering from mild to moderate AD. XPro1595 will be administered once per week over the course of three months. Biomarker inflammation will be assessed in the mid and end points of the trial.

Based in La Jolla, California, INmune Bio is a diversified, clinical-stage biotechnology company working to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. With its programs in oncology and neurodegenerative disease, the company offers significant investment opportunities with a considerable ROI.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• Companies like INmune Bio are advancing the development of innovative treatment methods
• INmune’s lead drug candidate, XPro1595, works by targeting neuroinflammation, one of the causes of Alzheimer’s
• XPro1595 is set to undergo a phase I clinical trial in the summer of 2019 with a goal of measuring traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer’s

The global market for Alzheimer’s disease (AD) treatments is forecast to double in value by 2023, reaching $4.9 billion, according to GlobalData research (http://ibn.fm/8ZqMy). The growth rate has been estimated at 10.5 percent for the forecast period.

The increasing prevalence of Alzheimer’s disease, advanced diagnostic capabilities and technological advances are all expected to contribute to the future growth. Companies like INmune Bio Inc. (NASDAQ: INMB) are working hard on such technological and pharmaceutical advances. The clinical-stage immunology company is developing novel therapies that affect a specific part of the patient’s immune system to produce a disease-fighting response.

The company’s drug candidate, XPro1595, targets neuroinflammation – one of the causes of AD.

In June 2019, Pfizer researchers announced an important discovery highlighting the connection between neuroinflammation and AD. Medications that work in a manner similar to XPro1595 reduce the risk of AD development by as much as 64 percent. The Pfizer research confirms previous studies on the topic. A 2016 analysis of 8.5 million individuals showed that patients given medications suppressing neuroinflammation were less likely to develop AD than controls (http://ibn.fm/FCxY8).

An association between inflammation and Alzheimer’s disease has long been established. Until present, however, this link and the way in which it could be used to offer reliable AD treatments have both been overlooked. Numerous inflammatory markers are found in AD patients and several studies establish a link between chronic inflammation and the development of AD.

XPro1595 works by targeting the microglial immune cells of the brain. These cells are activated in many AD patients. They cause neuroinflammation that kills nerve cells and promotes synaptic dysfunction. Combined, these two effects lead to dementia in people with AD.

XPro1595 is currently undergoing strenuous testing. A three-month, phase I trial will involve 18 patients and will be carried out in the summer of 2019. Through the trial, INmune Bio will measure traditional and novel biomarkers of inflammation in people with mild to moderate AD. The Alzheimer’s Association is supporting the trial financially through the provision of a $1 million grant.

Such clinical work is of especially high importance due to AD developments over the past few years. The prevalence of AD doubles every five years, a report titled ‘Alzheimer’s Disease – Competitive Landscape and Market’ suggests (http://ibn.fm/vnczv). The prevalence of the condition has reached 40 percent of the 90-94 age group. The World Health Organization (WHO) reports that AD prevalence is also set to increase by in those aged 65 or older, from 6.8 percent in 2000 to 16.2 percent by 2050. The prevalence of dementia as a consequence is anticipated to increase from 24 million cases in 2005 to 81 million cases in 2040.

Based in La Jolla, California, INmune Bio is a diversified clinical-stage biotechnology company working to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. With its programs in oncology and neurodegenerative disease, the company offers intriguing investment opportunities.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• Organigram has distribution in all 10 Canadian provinces and has now received licensing approval from Health Canada for its Phase 4A expansion efforts, which are expected to bring its annual production capacity to 61,000 kg
• The company is well-positioned for Canada’s anticipated edibles and derivative legalization, expected in October 2019, with expanding production capacity, R&D and various strategic partnerships
• Phase 4 construction is on track for completion by the end of 2019, with an aim of increasing target production capacity to 113,000 kg per year once fully licensed and operational

Organigram Holdings Inc. (NASDAQ: OGI) (TSX.V: OGI) is pursuing an aggressive expansion strategy as Canadian cannabis consumers look forward to the country’s legalization of edibles and other derivatives that could be found on retail shelves as early as mid-December 2019.

Organigram recently announced that it has received Health Canada approval for the licensing of all of its Phase 4A buildout plans for total licensed production capacity of 61,000 kg per year, according to the news release (http://ibn.fm/jGAdq). Once fully licensed and operational, the full Phase 4 expansion is expected to bring the company’s annualized target production capacity to approximately 113,000 kg of dried flower equivalents.

“Organigram’s continued expansion reflects ongoing growth in the cannabis marketplace, including increasing demand as new retail stores come online in Alberta, Ontario, Quebec and British Columbia,” CEO Greg Engel said in a news release. “The expansion of our facility and production capacity will help ensure we have additional product for extraction for the launch of the edibles and derivatives market before the end of 2019.”

Organigram has also received organic certification for its recreational cannabis plants and growing processes from Pro-Cert, a North American certification body that is accredited to provide certificates under Canadian Organic Standards (http://ibn.fm/aEn5u). As a licensed producer of medical and adult-use recreational cannabis with production facilities and an R&D program in Moncton, New Brunswick, Organigram is one of the most experienced organic producers in the industry.

“We know that there is a significant consumer demand for organic cannabis products,” Engel stated. “We have been proud to offer our medical customers access to organic strains and are excited to be able to expand our offering to adult recreational consumers who value organic options.”

The company is also refurbishing part of its facility at its Moncton Campus in order to pursue Phase 5 development of a cannabis edibles and derivatives facility and additional extraction capacity. The company has committed to invest C$15 million in a chocolate production line, with capacity of up to four million kilograms of chocolate cannabis edibles per year (http://ibn.fm/fjjEz).

Organigram has secured several key partnerships and is developing a diverse product line to capture a large portion of the vape pen segment, which is estimated to account for 23 percent of the recreational cannabis market in Canada. Organigram is one of only four Canadian suppliers for the Pax Era premium oil vaporizer and will offer Edison Cannabis Co.-branded PAX Era pods to all 10 of its provincial partners to achieve coast to coast distribution (http://ibn.fm/VTzk8). Organigram also announced, through the Edison Cannabis Co. brand, that it will be the exclusive Canadian supplier of Feather Company’s design-patented disposable vaporizer and 5/10 thread cartridges. This agreement reflects both companies’ commitment to transformative thinking a­­nd unique customer experiences (http://ibn.fm/UPth7).

Most recently, the company shared plans to launch a variety of dried powder formulation beverages early 2020 in Canada. These products will leverage the company’s proprietary nano-emulsion technology, developed based on analytical testing, to create products with an initial onset of 10-15 minutes. At the same time, the company is also actively seeking a strategic partner with proven experience in beverage product development to take advantage of the liquid formulation that it has developed (http://ibn.fm/8JeN6).

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• The global industrial hemp market is projected to grow from $4.6 billion in 2019 to $26.6 billion by 2025, at a CAGR of 34 percent
• Green Hygienics is authorized for commercial production of industrial hemp in California and Michigan and has plans to expand its cultivation capabilities to multiple states
• Green Hygienics is moving to purchase the Potrero Ranch property near San Diego, California, which offers ideal conditions for hemp cultivation

Green Hygienics Holdings Inc. (OTCQB: GRYN), an innovative, science-driven premium cannabis cultivation and branding enterprise, is gaining momentum in its bid to expand the company’s cultivation capabilities to multiple states. Green Hygienics recently reported that it has secured a registration from the County of San Diego Department of Agriculture, Weights and Measure as an industrial hemp cultivator (http://ibn.fm/dNV6B). With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis and hemp cultivation systems.

“On course with our pursuit of worldwide traction, we are pleased to gain ground in California, where the cannabis industry continues to bear considerable opportunity,” Matt Dole, Green Hygienics vice president of business development, said a news release.

Green Hygienics is in the process of completing the purchase of the Potrero Ranch property near San Diego, which offers ideal conditions for hemp cultivation. Now in escrow, the ranch property will provide Green Hygienics Holdings with plenty of room to grow hemp in California (http://ibn.fm/7r6Vm). The Potrero Ranch property, consisting of 824 prime acres of prime pasture, will be used to cultivate hemp and provide a base of operations for several other equally exciting initiatives, Dole said.

“Given that there is the potential to harvest 1,200 to 1,500 pounds of hemp per acre, we can produce two crops per year, and with the price of hemp at an average of $50 per pound, this initiative has the potential to produce significant revenues for the Company,” Dole stated in a news release announcing the planned purchase (http://ibn.fm/IxAfa).

Additional potential at the Potrero Ranch property is in the existing outbuildings, spanning 294,000 square feet, which are ideal for use as greenhouses or seed production and storage. The property also includes an updated home, an abundant water supply and soil with the type and pH levels identified as ideal for hemp cultivation.

New Frontier Data estimates that the hemp-derived CBD market in the United States will grow to a $1.3 billion market by 2022, tripling in size from $390 million in 2018 (http://ibn.fm/dtzcQ). Changes in public opinion about cannabis, an unprecedented year for passage of state-level reforms and legalization of hemp under the 2018 Farm Bill have all contributed to high expectations for the cannabis and hemp industries, as detailed by J.J. McCoy, senior managing editor of New Frontier Data, in an article for Yahoo Finance (http://ibn.fm/t85Hz).

Green Hygienics has also secured licenses for the cultivation and processing of hemp in Michigan. Licenses were granted to the company’s wholly owned subsidiaries, Green Hygienics Michigan LLC and Coastal Labs Michigan LLC, under the Michigan Department of Agricultural and Rural Development (MDARD) Industrial Hemp Ag-Pilot Program. Under the research agreement with MDARD, Green Hygienics is approved to plant, propagate, grow, cultivate and harvest live hemp plants or viable hemp seeds.

“Obtaining these licenses is complementary to our mission of becoming a leader in the advancement of science-driven cannabis cultivation systems. Michigan’s strong farming community produces 300 different commodities on a commercial basis, and we are pleased to be part of its continued growth,” Dole stated in a news release (http://ibn.fm/8NgA0).

ResearchandMarkets projects that the global industrial hemp market will grow from $4.6 billion in 2019 to $26.6 billion by 2025, recording a compound annual growth rate of 34 percent (http://ibn.fm/y09n9). Increasing legalization in the cultivation of industrial hemp and the functional properties of hemp seed and hemp seed oil, which includes the increasing use of cannabidiol (CBD) in consumer goods and pharmaceuticals, are projected to drive market demand, the report states.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• IONIC has grown from a family-run business selling vape pens in Washington state to an award-winning cannabis holding company with a multi-state portfolio
• The IONIC Premium Vape Pen holds a consistent spot in the top 10 vape brands in Washington, bringing in $9.9 million in sales in 2018
• The company set the bar for trust and transparency in cannabis retail by partnering with Lucid Green to create the first-ever direct-to-consumer platform providing product-specific information

A family-run business that began by selling vape pens in Washington state is now a publicly traded company positioned to take recreational cannabis nationwide and with an international patent currently pending. West Coast-based cannabis holding company IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) has built a multistate portfolio of award-winning products.

Headquartered in Washington, where it all began, the company is rapidly expanding throughout the United States, reaching first into Oregon, California and Nevada, with its products currently sold in 685 stores across six states, and plans in place to continue expansion into other states throughout the year. The company is focused on organic, bottom-up growth as it cultivates and delivers recreational cannabis products to consumers nationwide.

IONIC Brands only recently went public and has made multiple strategic acquisitions in a short period of time. According to CEO and Board Chairman John Gorst (http://ibn.fm/PT9Ni), the company’s goal is to own the top four markets in the United States. “What we’re focused on is owning the West and winning the rest,” Gorst noted in a news release. “We believe that we’re going to achieve a billion-dollar market valuation.”

According to projections, the company is well on its way to reaching this goal. Recent acquisitions are believed to have added more than $30 million in revenue this year, with total revenues projected to reach a total of $46 million for 2019.

The company’s flagship recreational-branded product, the IONIC Premium Vape Pen, holds a consistent spot in the top 10 vape brands in Washington state. The vape pen was launched in 2015 and finished 2018 with $9.9 million in sales, reaching those impressive numbers despite only being sold in three states; the pen is expected to finish 2019 with a much wider reach.

IONIC products are refined without the use of glycols, glycerins or additives. Every batch is individually tested through IONIC’s Certified Clean program, which is enhanced by the launch of the Lucid Green technology platform (http://ibn.fm/qPJTT). This platform enables consumers to access a library with product-specific information, including test results, dosage guidance and known effects. Lucid Green was released in May 2019 and was the first direct-to-consumer data platform in the cannabis industry.

“IONIC sets the bar for trust and transparency in California by partnering with Lucid Green to ensure that consumers have all the information they need to have a safe, consistent and enjoyable experience,” added Lucid Green co-founder and CEO Larry Levy. “Everyone knows how to take a photo with their phone. It’s like getting personal guidance from the most knowledgeable budtender in the world — by just aiming your phone at the product in your hand and clicking on the link that pops up! We created Lucid Green to create a standard that drives trust, transparency and guidance in the cannabis retail environment.”

IONIC is dedicated to providing consumers across the country with the finest small-batch cannabis oils and cannabis concentrates in the world. The company aims to set the standard for transparency and create a brand that consumers and investors can trust.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to IONKF are available in the company’s newsroom at http://ibn.fm/IONKF

• DVLP provides business services and products for the cannabis industry
• The company’s focus is on cannabidiol and ancillary software
• DVLP is in the process of moving into a new production facility in Denver

Golden Developing Solutions Inc. (OTC: DVLP) is an emerging leader in the CBD (cannabidiol) products marketplace and ancillary software. Golden Developing Solutions provides business services and products supporting the cannabis industry, including an online retail business for CBD, hemp oil and other health- and wellness-related products.

Additionally, Golden Developing Solutions is concentrating on acquisitions of CBD firms that are in compliance with state and federal laws. Fundamentally, the company focuses on two basic sectors for growth: CBD and ancillary software. DVLP recently launched a new software division featuring a website allowing cannabis growers to obtain information and communicate with one another (www.GreenerGrows.org).

Golden Developing Solutions also acquired Where’s Weed and its main asset, WheresWeed.com. Where’s Weed is an American cannabis-technology company that connects medical and recreational cannabis users with trusted local businesses in their communities. Where’s Weed offers a sophisticated mobile application with strong traction and robust growth potential. WheresWeed.com has a large and expanding reach, and the Where’s Weed mobile app is available for both iOS and Android.

Golden Developing Solutions is in the process of moving into its new 25,000-square-foot production facility in Denver, Colorado. This facility will house main production for the company’s wholly owned subsidiary, Infusionz LLC (“CBD Infusionz”). CBD Infusionz is a premium manufacturer of superior CBD products.

“We are excited to get into the new facility, get organized and ramp up operations,” DVLP CEO Stavros Triant stated in a news release. “This is a massive expansion of our overall production footprint, and we anticipate a correspondingly massive expansion in our growth rate and the value proposition we offer our shareholders. That represents a very strong position for the company, particularly following passage of Colorado House Bill 1090 last month.”

Of significance for Golden Developing Solutions is the passage of House Bill 1090, which allows publicly traded companies to have cannabis licenses. Moreover, the bill permits more investments in Colorado’s cannabis industry by venture capitalists and other private equity firms by removing the limit of 15 out-of-state owners per cannabis company.

Golden Developing Solutions is advancing its vision of leading CBD culture into the contemporary world. The company represents a dynamic investment opportunity, as it focuses on first-class products, CBD branding and the acquisition of recognized brands. Golden Developing Solutions continues an upward growth trajectory as it further develops its direct marketing strategy through its primary online retail channel.

For more information, visit the company’s website at www.GoldenDeveloping.com

NOTE TO INVESTORS: The latest news and updates relating to DVLP are available in the company’s newsroom at http://ibn.fm/DVLP

• VPR Brands develops products for the vaping market
• The company recently launched its new dry-herb vaporizer
• VPR continues to experience strong financial results as it builds its product portfolio

VPR Brands LP (OTC: VPRB) is a technology holding company based in Fort Lauderdale, Florida, that continues to drive scale across diverse high-growth verticals. With its award-winning design and diligent product innovation, VPR Brands offers investors a gateway to the vape products marketplace.

VPR Brands boasts an extensive portfolio of tested vaporizer products. Its product suite includes Helium, HoneyStick, Vaporin, Vaporx, GoldLine and GoldLine Hemp products and brands. VPR is taking advantage of a line of CBD (cannabidiol) products to boost growth and gain market share in the cannabis-consumables sector. The company has likewise reported robust year-over-year financial growth, with room for margin improvement, as well as category growth (http://ibn.fm/iHdTq).

Recently, VPR Brands announced the launch of its HRB Turbo Dry Herb Vaporizer by HoneyStick. The HRB Turbo is an ultra-premium, pocket-sized, dry-herb vaporizer that’s available for $99. “The HRB Turbo is the best dry-herb vaporizer with an MSRP under $100 currently on the market,” VPR Brands COO Dan Hoff stated in a news release (http://ibn.fm/8c46d). “The luxurious feel and performance of the unit makes it truly a great value for anyone on the market for a top-tier pocket vaporizer that doesn’t want to spend an arm and a leg. With many of our clients requesting us to make more products for dry herb, it’s a perfect fit into our product line.”

CNW420 recently reported on New Mexico cannabis decriminalization following signing of a bill by New Mexico Governor Michelle Grisham that took effect on July 1, 2019. This law makes New Mexico the 24th state to decriminalize marijuana. Governor Grisham has promised to pursue marijuana legalization in New Mexico. She has created a working group to study legalization in other states and prepare recommendations about the best way to handle legalization next year. Cannabis industry commentators believe that industry participants, including VPR Brands, will be relieved that New Mexico has provided good news to break the chain of legislative setbacks (http://ibn.fm/PvFz5).

VPR Brands has developed a curated product mix to drive sales. That mix includes vaporizers, e-liquids, cannabis consumables, disposable vapes, batteries and tanks. Together, this product mix works to meet consumers’ needs and create synergies across the company’s brands.

VPR is seeing growth, including quarterly revenues that increased by roughly 31 percent year-over-year to $1.3 million. Moreover, the company slightly decreased its net loss from about $149,000 in Q1 2018 to approximately $138,000 in Q1 2019. VPR also continues to maintain healthy gross operating margins of greater than 40 percent (http://ibn.fm/O9aCd).

VPR Brands also reported positive financial results for full-year 2018, including increased revenues totaling an estimated $4.6 million. In addition, the company reversed its operating loss of more than $888,000 into positive territory above $9,000. Full-year 2018 gross operating margins rose by nearly 20 percent from 2017 to a margin of 41 percent last year (http://ibn.fm/KeO2S).

Company assets include issued U.S. and Chinese patents for atomization-related products. Its patents include technology for medical marijuana vaporizers and electronic cigarette products and components. Additionally, the company engages in product development for the vapor and vaping market, including e-liquids. VPR Brands has a seasoned management team with wide-ranging experience in the vaporizer category.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• Trxade Group subsidiary Community Specialty Pharmacy received certification from LegitScript following a rigorous application and review process
• Over 10,500 independent pharmacies are registered on Trxade’s S2P (supplier to pharmacy) pharmaceuticals trading platform
• The company’s first quarter 2019 revenues increased to a record $1.5 million

Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical services company, is focused on three key niches in the health care market, a $4 trillion industry that’s expected to grow as the general population ages. TRXD offers a unique combination of a web-based purchasing platform for transactions between independent pharmacists and drug distributors; a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services.

TRXD is off to a record start this fiscal year, with reported Q1 2019 sales of $1.5 million (http://ibn.fm/lbyhN). Revenue growth was attributed to an increase in fees generated from the company’s supplier-to-pharmacy trading platform and increased pharmaceutical sales from its wholly owned subsidiary, Community Specialty Pharmacy LLC.

In Q1 2019, TRXD added more than 400 new independent pharmacies to the Trxade software trading platform, bringing the membership total to over 10,500 pharmacies. There are more than 24,000 independent pharmacies in the United States with combined pharmaceutical purchases of $93 billion per year.

“Our proprietary software trading platform at www.Trxade.com, which enables independent pharmacies to purchase drugs, is adding new members on a monthly basis and, as a result, is enabling us to experience strong top and bottom-line growth across the board,” Trxade Group Chairman and CEO Suren Ajjarapu said in a news release.

Community Specialty Pharmacy (“ComspRx”) has carved out a niche in the highly competitive pharmacy industry with a patient-driven approach. Importantly, ComspRx has secured LegitScript certification following a rigorous review process. LegitScript approval is known throughout the online advertising, social media, regulatory and payment sectors and is recognized by Visa, Mastercard, Google, Bing and others. Certification lets customers know ComspRx is committed to best-in-class pharmacy programs and operates safely and legally in a highly regulated health care marketplace, as TXRD noted in a news release (http://ibn.fm/mwkZQ).

“LegitScript certification is another way for us to help consumers understand their options and choose a pharmacy that has their best interests, and long-term health in mind,” Ajjarapu said in a news release, adding that ComspRx is dedicated to assessing a patient’s unique requirements and prescriptions and providing top-tier, comprehensive and compassionate care.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD